Eli Lilly (LLY 1.53%) announced earnings recently, and the results weren't good. Revenue fell 16%, and net income dropped an eye-popping 53%. Lilly is in a transition period as generic competition eats away at well-known franchises, but the company had pipeline success from Cyramza and is executing deals to bolster its overall business, including increasing Elanco to the second largest animal health player.

In this segment from Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass take investors through some of the key numbers to know from Eli Lilly's report this quarter. David looks through several of the sales numbers for the pharmaceutical conglomerate's key products, notes one piece of good news from the report, and discusses some of the near-term challenges he sees facing the company today.